Skip to main content

Table 4 Median percent change from baseline in biomarker concentration in patients who achieved or did not achieve LDA (DAS28-CRP <3.2) at week 24

From: Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY

 

Placebo

Sarilumab 200 mg q2w

LDA achieved

(n = 37)

LDA not achieved

(n = 91)

LDA achieved

(n = 72)

LDA not achieved

(n = 59)

CRP

 Week 2

1.2

−2.9

−95.0**

−83.5

 Week 24

−31.9**

−4.2

−96.9**

−90.2

C1M

 Week 2

4.5

2.2

−55.8*

−45.1

 Week 24

−16.8*

−4.3

−65.7**

−54.1

C2M

 Week 2

0

3.4

0*

−14.3

 Week 24

0

3.5

0

−6.7

MMP-3

 Week 2

−2.0

2.3

−7.2

−3.3

 Week 24

−9.7

0.4

−47.2

−34.2

OPG

 Week 2

−5.1

1.6

−6.5*

−0.9

 Week 24

−1.9

−1.8

−4.6

0.9

sRANKL

 Week 2

−4.7

−0.8

−7.9

−2.3

 Week 24

−16.2*

−0.8

−39.7

−25.8

  1. Percent change from baseline in biomarkers transformed in rank was compared between responder and nonresponder patients at week 24 using an analysis of variance (ANOVA)-type method, with response, visit, and response-by-visit interaction as fixed effects, rank-transformed baseline biomarker value and rank-transformed baseline biomarker-value-by-visit interaction as fixed covariates, and assuming an unstructured covariance structure. The model was run separately by treatment group (sarilumab 200 mg q2w and placebo).
  2. C1M collagen type I MMP-cleaved fragment, C2M collagen type II MMP-cleaved fragment, CRP C-reactive protein, DAS28-CRP 28-joint disease activity score by CRP, LDA low disease activity, MMP matrix metalloproteinase, MTX methotrexate, OPG osteoprotegerin, q2w every 2 weeks, sRANKL soluble receptor activator of nuclear factor-kB ligand. *Nominal p < 0.05 vs nonresponder. **Nominal p < 0.01 vs nonresponder